RenovoRx, Inc. (RNXT)

↓ Download CSV

CIK 0001574094 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, RenovoRx, Inc. reported revenue of $1.12M, up 2511.6% from the prior year. The company ran a net loss, with a net margin of -994.5% and a gross margin of 70.9%. It held $8.10M in total assets against $2.67M in total liabilities.

Key ratios (FY2025)

70.9%
Gross margin
-1114.0%
Operating margin
-994.5%
Net margin
-206.0%
Return on equity
+2511.6%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$1.12M$43.0K
Cost of Revenue$327.0K$0
Gross Profit$796.0K$43.0K
Operating Income-$12.51M-$10.97M-$11.40M-$9.95M-$5.67M-$3.20M
Net Income-$11.17M-$8.81M-$10.23M-$9.89M-$6.32M-$3.80M
EPS (Diluted)$-0.32$-0.40$-0.99$-1.09$-1.21
Total Assets$8.10M$8.12M$1.47M$7.26M$16.29M$1.91M
Total Liabilities$2.67M$3.64M$4.47M$1.10M$938.0K$4.12M
Shareholders' Equity$5.42M$4.48M$3.00M$6.16M$15.35M-$14.66M-$10.93M
Cash & Equivalents$7.02M$7.15M$1.17M$4.39M$15.19M$1.79M
Operating Cash Flow-$10.97M-$9.12M-$10.26M-$8.81M-$5.92M-$3.53M
Capital Expenditures$2.0K$12.0K
Shares Outstanding36.61M24.03M10.69M9.10M8.93M2.23M